The promise of comprehensive metabolic improvement through single interventions has driven intense interest in GLP-1 receptor medications, yet determining which formulations deliver the broadest cardiometabolic benefits has remained unclear. This systematic comparison could reshape treatment decisions for millions managing both weight and metabolic dysfunction.
Analyzing 19 randomized trials encompassing over 13,000 adults, investigators developed a composite cardiometabolic efficacy index scoring seven key health metrics: weight loss percentage, triglycerides, HDL and LDL cholesterol, waist circumference, HbA1c, and systolic blood pressure. Semaglutide 7.2mg achieved the highest composite score of 0.86, followed by orforglipron 36mg at 0.68 and semaglutide 2.4mg at 0.66. All three formulations produced placebo-adjusted weight reductions exceeding 10 percent. Among oral preparations specifically, orforglipron 36mg performed comparably to oral semaglutide 25mg.
This network meta-analysis provides crucial guidance for clinicians navigating an increasingly complex landscape of GLP-1 medications. The composite scoring approach represents a significant methodological advance, moving beyond isolated weight loss metrics to capture comprehensive cardiometabolic impact. However, the analysis inherits limitations common to network meta-analyses, including indirect comparisons and heterogeneous study populations. The consistency of rankings across diabetic and non-diabetic subgroups strengthens confidence in the findings. For practitioners, these results suggest higher-dose formulations may justify their cost through broader metabolic benefits, though individual patient factors and tolerability profiles remain paramount in treatment selection.